Low-dose Naltrexone Changes Levels of Inflammatory Proteins in MS, Study Shows
MS News Today
20 February 2018
Review of study "Modulation of the OGF–OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis", in Exp Biol Med (Maywood), January 20018, https://journals.sagepub.com/doi/10.1177/1535370217749830
For many years, researchers at Penn State focused on understanding the benefits of low-dose naltrexone and its relation with OGF in health and disease, including MS. Their discovery of dysregulation in OGF expression in MS patients, and animal models could lead to prognostic biomarkers for this autoimmune disorder.